Evaluating the Correlation Between Serum PSA Values and Gleason Score of Prostate Carcinoma with Ga68-PSMA Uptake in Prostate Tumor in Primary Staging
نویسندگان
1 Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
2 Kidney Transplant Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
3 Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
4 School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
5 Nuclear Medicine Department, Razavi Hospital, Mashhad, Iran
6 Kidney Transplant Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
7 Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
8 School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
9 Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
10 Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
11 Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
doi
10.22034/tru.2024.451836.1182چکیده
Introduction: Ga68-PSMA PET/CT plays a crucial role in staging, evaluating treatment, and diagnosing local recurrence of prostate tumors. Recently, the NCCN guidelines have recommended it as the preferred staging method for unfavorable intermediate and high-risk patients. This study aims to evaluate the correlation between serum PSA levels and Gleason score of prostate tumors with the findings of Ga68-PSMA PET/CT scans in primary staging.Methods: In this cross-sectional study, patients with newly diagnosed prostate cancer referred for Ga68-PSMA PET/CT whole-body scans were enrolled. The scans were performed at three time points (early, whole-body, and late). The standardized uptake value of Ga68-PSMA in the primary tumor and its association with serum PSA levels, tumor Gleason score, and presence of tumor metastasis were evaluated and analyzed. A p-value<0.05 was considered statistically significant in all statistical analyses.Results: A total of 49 male patients with a median age of 65 years (Interquartile range: 59-69) were included in the study. Of these patients, 43.9% were classified as high-risk based on their Gleason score. The median serum PSA level was 17 ng/mL (Interquartile range: 8.02-42.10). PSA levels correlated with the SUVmax of the tumor in the whole-body stage of the scan (P-value<0.05; r=+0.392), but not in the early or late stages (P-value>0.05). Gleason scores showed a positive correlation with tumor SUVmax in all three scan stages (P-value<0.05).Conclusion: Our results indicate that the Gleason score significantly correlates with the SUVmax of the prostate tumor in all three time points of the scan. However, serum PSA levels only correlate with the tumor SUVmax in the whole-body stage of the scan, not in the early and late stages. In the whole-body stage, a higher SUVmax is significantly associated with higher Gleason scores ,bladder wall and seminal vesicle invasion, and lymph node metastasis (P-value<0.05 in all cases).
